Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can new pills tame high blood pressure?

NCT ID NCT06291207

Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This clinical trial is testing whether two experimental oral medications, AD-224A and AD-224B, can safely lower blood pressure in people with essential hypertension (high blood pressure with no known cause). About 254 participants will take one of the drugs or a placebo once daily for 8 weeks. The main goal is to see how much the drugs reduce sitting systolic blood pressure compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AD-224A and AD-224B (oral drugs taken once daily for 8 weeks)
What this could lead to
If successful, these oral medications could offer a new option for controlling high blood pressure, potentially reducing the risk of heart attack and stroke.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drugs may not lower blood pressure enough or could cause side effects. Success in this trial does not guarantee approval or widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

254 people

The number who actually took part.

Started

Apr 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension,essential are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension,essential

Contacts and locations

Locations

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.